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Summary
BACKGROUND: During the last 20 years, treatment for
chronic lymphocytic leukaemia (CLL) / small lymphocytic
lymphoma (SLL) has advanced, with improved clinical out-
comes in randomised controlled trials. Currently, no data
have been published from Switzerland to assess effective-
ness of recent healthcare advances in CLL/SLL on a pop-
ulation-based level. We aimed to estimate trends in inci-
dence, mortality and survival for patients with CLL/SLL in
Switzerland.
METHODS: We retrospectively studied registry data from
the National Agency for Cancer Registration (NACR) data-
base in Switzerland from 1997 to 2016. We investigated
incidence, mortality and survival in consecutive 5-year pe-
riods. Age-specific rates were calculated for three age
groups (<65 years, 65–74 years and ≥75 years).
RESULTS: We obtained 6301 cases with CLL/SLL. Medi-
an age at diagnosis was 72 years. From 7.0 per 100,000
person-years in 1997–2002, age-adjusted incidence rates
peaked at 7.8 per 100,000 person-years in the second
time period, 2002–2006, and declined afterwards to 6.4
per 100,000 person-years in 2012–2016. Mortality de-
clined from 2.4 per 100,000 person-years in 1997–2002
to 2.0 per 100,000 in 2012–2016. Five- and 10-year age-
standardised relative survival increased from 77.9% and
55.6%, respectively, in 1997–2001 to 83.6% (p = 0.009)
and 64.2% (p = 0.005), respectively, in 2012–2016. Im-
provement in age-specific relative survival was only signifi-
cant in the middle age group (65–74 years). Incidence and
mortality were significantly higher in males. Females had
better relative survival.
CONCLUSION: We found no clear down- or upward trend
in age-adjusted incidence rates. Age-standardised sur-
vival improved over time, mainly in the two younger age-
groups, but this improvement was statistically significant
in those aged 65–74 years only. Males have higher inci-
dence rates, higher mortality and shorter survival than fe-
males. Reporting delay and underreporting are major lim-
itations in the interpretation of registry data from patients
diagnosed with CLL/SLL.
Introduction
Chronic lymphocytic leukaemia (CLL) / small lympho-
cytic lymphoma (SLL) is the most prevalent leukaemia
and the second most common B-cell neoplasm in Western
countries [1, 2]. It affects mostly elderly persons with a
median age at diagnosis of 72 years and a male:female ra-
tio of 2:1.
Despite the double name, CLL/SLL is one disease, char-
acterised by neoplastic monomorphic small mature B cells
with a particular morphology and immunophenotype as de-
fined by the current World Health Organization (WHO)
classification [1, 3]. The WHO classification defines SLL
as a subtype of CLL/SLL representing the nodal equivalent
of CLL without leukaemic manifestation. About 10–20%
of CLL/SLL cases are SLL.
Historically, CLL/SLL was first considered as one entity
in the REAL classification of 1994. Earlier classifications
usually categorised CLL and SLL as distinct diseases. SLL
in particular was defined less stringently in classifications
based solely on morphology and not including im-
munophenotypic criteria. Therefore, in some older classi-
fications, SLL also included other B-cell neoplasms com-
posed of small lymphocytes, such as marginal zonal
lymphomas, Waldenström macroglobulinaemia, mantle
cell lymphoma or T-cell proliferative disorders.
Irrespective of its presentation as the leukaemic or nodal
variant, CLL/SLL is heterogeneous regarding the sequen-
tial somatic genetic lesions underlying leukaemogenesis,
localisation, clinical manifestation and disease course.
Many patients present in an asymptomatic stage not requir-
ing immediate treatment at diagnosis [1, 4, 5].
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Treatment of CLL/SLL has undergone considerable
changes in Switzerland, as in many other countries. Mono-
and combination chemotherapy, based on alkylating agents
such as chlorambucil and cyclophosphamide since the
1960s and purine analogues such as fludarabine and
cladribine since the 1980s [6, 7], was the mainstay of treat-
ment until after 2000. After 2000, chemoimmunotherapies
combining alkylating agents and/or purine analogues with
anti-CD20 antibodies became standard, justified by im-
proved clinical outcomes in randomised controlled trials
[8–12]. Recently, new small molecules, such as the B-
cell receptor kinase inhibitors, including the Bruton tyro-
sine kinase (BTK) inhibitor ibrutinib [13] and the phos-
phatidylinositol-3-kinase p110δ inhibitor idelalisib [14], as
well as BCL-2 inhibitors such as venetoclax [15], im-
proved outcomes in clinical trials.
Population-based studies from different Western countries
reported improvement in survival: from Denmark between
1978 and 2013 [16], from Norway between 1952 and 2012
[17], from Germany and the USA between 2003 and 2011
[18]. So far, no recent population-based data have been
published from Switzerland.
In this study, we analysed trends in incidence, mortality
and survival of patients with CLL/SLL in Switzerland be-
tween 1997 and 2016. We investigated sex- and age-spe-
cific trends for age groups <65, 65–74 and ≥75 years. We
were particularly interested to investigate whether the sur-
vival benefits reported from clinical trials translate into im-
proved relative survival in CLL/SLL patients on a popula-
tion level.
Methods
Data sources and inclusion criteria
The National Agency for Cancer Registration (NACR)
database provided incident CLL (ICD-O-code 9823/3) and
SLL cases (ICD-O-code 9670/3) for the years 1997–2016
and corresponding vital status information. Cases were
mutually exclusively coded as either CLL or SLL. NACR
collects and harmonises cantonal cancer registry data and
provides a central national database of cancer registration
data in Switzerland. A detailed description of the organi-
sation of cancer registration in Switzerland can be found
elsewhere [19]. In 1997–2001, 13 out of 26 cantons con-
ducted cancer registration (supplementary table S1 in the
appendix), covering 57.8% of the Swiss population. As of
2016, this number increased to 23 cantons. However, at the
time the analyses were carried out, three cantons (Gene-
va, Basel-Stadt and Basel-Landschaft) could not yet pro-
vide data for the incidence year 2016, resulting in popu-
lation coverage of 85.2% for the last observation period.
Incidence years covered by each canton are shown in table
S1. Overall, 94.1% of all CLL/SLL cases were morpholog-
ically verified (table S2).
The Swiss Federal Statistical Office (SFSO) supplied mor-
tality data, mid-year population estimates and cantonal
death rates by age, sex and calendar year, covering all per-
sons with permanent residence status in Switzerland. The
SFSO codes death certificates and selects the underlying
cause of death for the whole of Switzerland. Causes of
death were coded according to the tenth revision of the In-
ternational Classification of Diseases and Related Health
Problems (ICD-10). Underlying cause of death is selected
from the causes and conditions entered on the death certifi-
cate. When more than one cause or condition is entered on
the certificate, ICD international rules for selecting the un-
derlying cause of death apply [20]. We calculated mortality
for the ICD codes C83.0 (small cell B-cell lymphoma) and
C91.1 (chronic lymphocytic leukaemia of B-cell type).
Ethics approval and consent to participate
No informed consent of the patients was necessary for this
study. The data were collected and aggregated according to
cantonal and state-wide provisions for the purpose of mon-
itoring cancer burden, care and outcomes, and were pro-
vided and used for this study according to the respective
legal regulations and approved by the Ethics Committee
Zurich (KEK-ZH-Nr. 2014-0382, PB_2016–01643). The
analyses were carried out by the National Institute for Can-
cer Registration and Epidemiology (NICER) until the end
of 2019 and the National Agency for Cancer Registration
(NACR) from 2020 onwards. Data transmission to third
parties took place exclusively in aggregated form in accor-
dance with the Swiss Cancer Registration Act (CRA) and
Cancer Registration Ordinance (CRO) (CRA, Art. 23, par
1, 2; CRO, Art. 30, par 3, 4).
Analytical methods
The expected number of cases for all of Switzerland were
extrapolated by applying the observed sex-and age-specific
incidence rates (five-year age intervals) to the population
of all cantons, with the assumption of homogeneity of sex-
and age-specific incidence rates across regions with and
without cancer registration.
We calculated five-year age-specific, crude and age-stan-
dardised incidence and mortality rates with corresponding
95% confidence intervals (95% CIs) for consecutive five-
year periods between 1997 and 2016: 1997–2001,
2002–2006, 2007–2011, and 2012–2016. For the main
analyses, age-standardised rates were calculated using the
direct method and the European Standard Population 2013
[21] as reference. To increase comparability with other
studies, age-standardised rates were additionally calculated
using the European Standard 1976, Segi’s World Standard
and the new WHO Standard (WHO 2000–2025) [22]. The
expected number of cases for all of Switzerland were ex-
trapolated by applying the observed incidence rates to the
population of all cantons under the assumption of homo-
geneity between regions with and without cancer registra-
tion. To assess whether increases in population coverage
over time had an impact on observed incidence trends, we
performed sensitivity analyses excluding cantons starting
cancer registration after 1997.
Relative survival was calculated as the ratio of the ob-
served survival of cancer cases and the expected survival
of persons in the general population matching in age, sex,
calendar year and region of residence [23, 24]. Observed
survival was estimated based on transformation of the cu-
mulative hazards. Expected survival was calculated using
the Ederer II method [23]. We calculated observed and rel-
ative survival up to 10 years after diagnosis using period
analysis [24]. We performed age-stratified analyses for the
age categories <65 years, 65–74 years and 75+ years. Rel-
ative survival for all age groups combined were age-stan-
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dardised using weights from the International Cancer Sur-
vival Standards (ICSS-Standard 1) [25]. To compare 5- and
10-year relative survival, we applied the significance test
described by Parkin and Hakulinen [26].
Statistical analyses were performed by Stata/MP version
15.1 (STAT Corp., TX USA). All statistical tests are two-




Between 1997 and 2016, 6501 cases were reported in
Switzerland. Based on the reported cases and the coverage
of the registry, we expect a total of 9355 new cases for the
same time period in Switzerland. The median age at diag-
nosis was 71 years in males (interquartile range 62–78) and
73 years in females (interquartile range 65–81). Twenty-
eight percent of all patients were younger than 65 years at
the time of diagnosis. The demographic characteristics of
observed CLL/SLL cases are presented in table 1.
Incidence
Annual case frequencies averaged 408 and 488 incident
CLL/SLL cases for the time periods 1997–2001 and
2012–2016, respectively (table 2). Figure 1 depicts the cor-
responding rates by five-year age groups. In both sexes,
the age-adjusted incidence peaked in the second time peri-
od and decreased thereafter (fig. 2). The sensitivity analy-
ses excluding all cancer registries implemented after 1997
showed results similar to our main analyses (supplemen-
tary tables S6 and S7 in the appendix).
Sex-specific incidence rates were around twice as high for
males as for females across all age groups (fig. 1). For
both sexes, the age-specific incidence rate first increases
almost exponentially but flattens thereafter with a more
linear increase after around 60 years of age. Similarly,
Table 1: Patient characteristics of chronic lymphocytic leukaemia / small lymphocytic lymphoma cases reported to Swiss cancer registries, 1997–2016.
n % Median age at diagnosis (interquartile range)
Overall 6301 100.0% 72 (63–79)
Sex
Males 3723 59.1% 71 (62–78)
Females 2578 40.9% 73 (65–81)
Age
<65 years 1782 28.3% –
65–74 years 1987 31.5% –
75–84 years 2532 40.2% –
Time period –
1997–2001 1201 19.0% 72 (63–79)
2002–2006 1473 23.4% 71 (62–79)
2007–2011 1562 24.8% 72 (64–80)
2012–2016 2065 32.8% 71 (63–79)
Population covered by cancer registration: 57.8% in 1997–2001, 59.0% in 2002–2006, 65.1% in 2007–2011 and 85.2% in 2012–2016
Table 2: Incidence and mortality of chronic lymphocytic leukaemia / small lymphocytic lymphoma in Switzerland, 1997–2016.














Crude Adjusted§ Crude Adjusted§ Crude Adjusted§ Crude Adjusted§
Incidence
Overall 409 5.8 7.0 495 6.8 7.8 483 6.2 7.0 488 5.9 6.4
Sex
Males 231 6.7 9.6 290 8.1 10.8 281 7.3 9.4 305 7.5 8.9
Females 178 5.0 5.3 205 5.5 5.7 202 5.1 5.2 184 4.4 4.4
Age
<65 years 117 2.0 2.3 147 2.4 2.6 129 2.0 2.1 139 2.0 2.1
65–74 years 130 22.3 22.3 146 24.0 24.1 154 22.8 23.1 159 20.5 20.5
75+ years 162 31.8 31.7 202 36.0 35.9 201 32.5 32.3 191 28.4 28.2
Mortality¶
Overall 136 1.9 2.4 151 2.0 2.4 159 2.1 2.3 152 1.9 2.0
Sex
Males 74 2.1 3.6 84 2.3 3.7 87 2.3 3.3 87 2.1 3.0
Females 62 1.7 1.7 67 1.8 1.7 72 1.8 1.7 65 1.6 1.4
Age
<65 years 15 0.2 0.3 14 0.2 0.2 12 0.2 0.2 9 0.1 0.1
65–74 years 29 5.0 5.0 30 4.9 4.9 30 4.4 4.5 30 3.8 3.9
75+ years 92 18.2 18.4 107 19.1 19.1 117 18.9 18.7 114 16.9 16.5
* Incidence: mean annual case frequency extrapolated to the whole Swiss population from cases observed in the cancer registries. † Discrepancies between the sum and total
number of estimated incidence cases are caused by rounding errors. Mortality: mean annual case frequency derived from nationwide cause of death statistics. ‡ per 100,000
person-years. § European Standard 2013 ¶ Mortality: mean annual case frequency derived from nationwide cause of death statistics.
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the male:female ratios of age-adjusted incidence rate var-
ied only slightly across time periods (mean 1.88, range
1.81–2.02; fig. 2).
Incidence rates age-adjusted for common standard popula-
tions are provided in the appendix (table S4).
Mortality
Age-standardised rates of mortality also followed a down-
ward trend (table 2), from 2.4 deaths per 100,000 person-
years in 1997–2001 to 2.0 in 2012–2016.
Figure 1: Age-specific incidence and mortality of chronic lympho-
cytic leukaemia / small lymphocytic lymphoma by sex, time periods
1997-–001 and 2012–2016.(a) Incidence(b) Mortality
Figure 2: Age-standardised incidence and mortality of chronic
lymphocytic leukaemia / small lymphocytic lymphoma by sex and
time period(a) Incidence(b) Mortality
Mortality rates for males were around twice as high as for
females across all age groups. Both sex-specific mortal-
ity rates grew almost exponentially with increasing age,
reaching about 50 per 100,000 person-years for males and
about 25 per 100,000 person-years for females aged 85
years or older (fig. 1).
Crude and age-standardised incidence and mortality rates
were strikingly higher in males than in females across all
time periods. Age-adjusted mortality (mean 2.09, range
1.94–2.18) varied only slightly by time period, but the sex
ratio was higher for mortality than for incidence for all
time periods (fig. 2).
Mortality rates age-adjusted for common standard popula-
tions are provided in the appendix (table S5) for readers in-
terested in comparing our data with other populations.
Survival
Five-year age-standardised relative survival increased
from 77.9% (95% CI 74.2–81.2%) in 1997–2001 to 83.6%
(95% CI 81.0–85.8%) in 2012–2016 (p = 0.009). Ten-
year age-standardised relative survival rose from 55.6%
(95% CI 50.5–60.3%) in 1997–2001 to 64.2% (95% CI
60.4–67.7%) in 2012–2016 (p = 0.005; supplementary fig.
S1 in the appendix). These differences resulted from sig-
nificant improvement between the first and second time
period (p = 0.017 for 5-year relative survival and p = 0.007
for 10-year relative survival) without significant improve-
ment in pairwise comparisons of the subsequent time peri-
ods. Observed and relative survival were better in younger
patients (fig. 3). But improvement over time was signifi-
cant only for the middle age group: in patients diagnosed
below age 65 years 5-year relative survival improved from
88.8% (95% CI 84.0–92.5%) in 1997–2001 to 92.9% (95%
CI 89.5–95.5%; p = 0.117) in 2012–2016; in the age group
65–74 years relative survival increased from 78.7.0%
(95% CI 72.584.2%) to 87.3% (95% CI 82.8–91.0; p =
0.020); and for those aged 75 years or older 5-year relative
survival increased from 61.6% (95% CI 53.4–69.6%) to
65.2% (95% CI 59.0–71.2; p = 0.480) (figs 3 and 4).
Ten years after diagnosis, patients diagnosed between the
ages of 65 and 74 years again showed substantial im-
provements in relative aurvival, but not the other two age
groups: in those with age below 65 years from 71.0%
(95% CI 63.9–77.3%) in 1997–2001 to 78.4% (95% CI
73.1–83.0%) in 2012–2016 (p = 0.081); age 65–74 years
from 51.2% (95% CI 43.1–59.3%) to 67.5% (95% CI
60.8–73.8; p = 0.002); age group 75+ years 35.1% (95%
CI 24.7–47.4%) in 1997–2001 and 36.9% (95% CI
29.2–45.5%) in 2012–2016 (p = 0.793) (fig. 3). Relative
survival curves declined steadily over the whole observa-
tion time without evidence of a plateau. Detailed observed
and relative survival by age group and period are provided
in the appendix (table S6), as well as age-standardised sur-
vival curves (fig. S1).
Discussion
In this study we aimed to provide estimates and trends
of age-standardised, age- and sex-specific incidence rates,
mortality rates and time-dependent survival probability for
patients diagnosed with CLL/SLL. These are the first pub-
lished population-based data from CLL patients in
Switzerland over a long, recent time period.
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Incidence
Compared with other western countries, we find no obvi-
ous deviation in age-adjusted incidence for our data. This
estimation is very rough, and thorough comparisons be-
tween registry data from different countries is very limited
because of methodological variations: the selection of di-
agnosis codes in particular is not consistent between coun-
tries. CLL and SLL are not always seen as one entity.
For instance, the International Agency for Research on
Cancer (IARC) reports age-standardised incidence rates
(WHO world standard population) across selected Euro-
pean registries from 2008 to 2012 for males of between
2.4 and 8.8 and for females of between 1.0 and 5.9 [27].
This selection was based on ICD-10 and included cases
with code C91 (lymphoid leukaemias), which on one hand
Figure 3: Age-specific relative survival curves of chronic lympho-
cytic leukaemia / small lymphocytic lymphoma patients,
1997–2001 and 2012–2016.(a) Time period 1997–2001(b) Time
period 2012–2016
Figure 4: Relative 5-year survival after chronic lymphocytic
leukaemia / small lymphocytic lymphoma diagnosis by age-group
and time period
is not limited to CLL and on the other hand does not in-
clude all cases of SLL. Furthermore, CLL incidence in the
Netherlands between 1989 and 2008 was reported to be
slightly lower than ours: 5.1 per 100,000 person-years for
males and 2.3 to 2.5 for females (European standard pop-
ulation 1976). Aside from ICD-O codes 9670 and 9823,
the case selection in this study included additional codes
(9592, 9800, 9820 and 9823) [28]. In Germany, for ICD-
O codes 9823/3 and 9670/3 between 2001 and 2010 inci-
dence rates for men were 5.67 per 100,000 person-years,
for females 2.94, and for both sexes 4.12 (European stan-
dard population 1976) [29].
The increase in absolute incidence counts is explainable by
demographic changes. The skewed male:female ratio with
higher incidence in males is also known from other stud-
ies.
The change in diagnostic criteria is likely the main reason
for the lower incidence rates in recent years: in the NCI
1996 criteria, a cut off of >5 × 109/l B cells in peripheral
blood was required whereas IWCLL 2008 adjusted this
cell compartment to monoclonal B lymphocytes and intro-
duced the term monoclonal B-cell lymphocytosis for those
individuals with lower blood count and CLL immunophe-
notype. This change might have led to reclassification of
newly diagnosed patients, who would formerly have been
diagnosed with CLL/SLL, as monoclonal B-cell lympho-
cytosis.
In addition, reporting delay and underreporting may under-
estimate the true incidence rate. Reporting delay is an is-
sue for the estimation of CLL incidence, well known from
other cancer registries [30]. Reporting delay and under-
reporting might be a reason for lack of completeness of
lymphoid leukaemias in Swiss cancer registries. An eval-
uation of completeness among these registries has shown
high completeness for most cancer types except for lym-
phoid leukaemia [31].
Whereas reporting delay mainly affects recent years, un-
derreporting would bias the incidence rate toward lower
values across all time periods. The reason for these biases
with CLL are unclear. We speculate that diagnostic proce-
dures and the relatively long lasting (often several years)
asymptomatic phase before treatment may be key players.
In contrast to most neoplastic diseases, histological con-
firmation is not necessary to diagnose CLL. In line with
current guidelines [1, 32, 33] and from our experience in
clinical practice, we expect that most CLL cases are di-
agnosed from blood cell counts and flow cytometric im-
munophenotyping of peripheral blood. Therefore, in these
cases reporting relies solely on the diagnostic facilities per-
forming flow cytometry and the treating physician. As-
suming that pathology institutes report neoplastic diseases
consistently, we hypothesise that flow cytometry facilities
and physicians were less well implemented in the reporting
process during the analysed time period. The cancer reg-
istry classifies verification of the diagnosis into the cate-
gories morphologically, cytologically or others (table S2).
SLL diagnosis was consistently histologically verified in
more than 90% of cases across all time periods. In contrast,
the fraction of histologically verified CLL cases dropped
from 61% in the first to 40% in the last time period. The
fraction of cytologically verified diagnoses increased from
32% in the first to 56% in the last time period. The fraction
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of histologically verified CLL cases in the last time period
is still surprisingly high. Given these numbers and our ex-
perience of the clinical background, we question whether
all cytologically verified cases have been reported. Inter-
estingly, in a study on population-based data from Norway
the ratio of case numbers based on immunophenotyping
and cytology compared with histology was much higher
[17].
In clinical practice, histological confirmation is often not
done at diagnosis in asymptomatic states, but sometimes
at progression before initiation of treatment. In a relevant
number of cases, CLL might have been reported at the time
of first treatment but not when the disease was first diag-
nosed.
Mortality
Age-adjusted mortality rates significantly decreased over
time for males and females. As the Swiss cancer registry
data are not linked to information about therapy, we cannot
verify whether improved treatments had an impact on re-
duction of mortality.
The relative reduction in age-adjusted mortality was more
in the youngest age-group. This finding might be explained
by the introduction of fludarabine, cyclophosphamide and
rituximab, which was probably the most effective treat-
ment used for this age group in the time frame investigated.
Furthermore, fewer treatment-related deaths might have
reduced mortality.
The ratio of sex-specific age-adjusted mortality rates, with
more than two-fold higher age-adjusted mortality rates for
males compared to females, is even higher than the
male:female ratio of age-adjusted incidence rates, indicat-
ing that the increased mortality in males is not attribut-
able solely to the higher disease incidence in males. Sex
disparity in CLL outcome is well known from epidemio-
logical and clinical studies, with fewer adverse prognos-
tic markers (e.g., Binet stage, unmutated immunoglobulin
heavy chain variable [IGHV] genes, β2-microglobulin lev-
els, CD38 expression, Zap-70 positivity, TP53 aberrations
and 11q deletions) and better response to treatment (e.g., to
chlorambucil- and fludarabine-based regimens) in females
[34]. The reason for this sex disparity is not entirely un-
derstood, but it seems that biological factors mainly con-
tribute to these differences. For instance, effects of sexual
hormones [35], sex chromosome-dependent differences in
microRNAs [36] and different methylation patterns in CLL
cells [37] have been observed.
Survival
There was a trend to improved survival in the two younger
age groups, but improvement was significant in the 65–74
age group only.
We did not observe a shift of median age at diagnosis nor
from incident cases toward lower ages, which might indi-
cate lead-time bias due to earlier diagnosis in the asymp-
tomatic state. But our data might be not sensitive enough
to detect earlier diagnosis. We have no information on dis-
ease stages at time of diagnosis.
Advances in treatment in the earlier time periods brought
significant survival improvement: at this time, anti-CD20
antibodies and combination therapy were introduced into
CLL treatment. Given the results from randomised con-
trolled trials, we would expect that the introduction of
fludarabine, cyclophosphamide and rituximab for younger
patients might have contributed to the higher relative sur-
vival rates in those aged below 65 years [9, 12]. As men-
tioned before, we do not have linked data on treatments
to verify this hypothesis. The years of first approval in
Switzerland of drugs commonly used for treatment of
CLL/SLL may provide a rough frame work of time points
when they might have been used: chlorambucil 1957, cy-
clophosphamide 1960, fludarabine 1995, rituximab 1997,
alemtuzumab 2001, bendamustine 2009, ofatumumab
2011, obinutuzumab 2014, ibrutinib 2014, idelalisib 2015,
and venetoclax 2018[38, 39]. When we extrapolate the
possible use of each of these drugs, we have to keep in
mind that not all of them were first approved for treatment
of CLL/SLL, but rather for other neoplasms, particularly
other B-cell neoplasms. Unfortunately, we cannot reliably
infer whether they have been used as monotherapy or in
combination regimens. Furthermore, some of these drugs
may have been used in clinical trials or off-label in named-
patient programmes before approval. Interestingly, the sur-
vival improvement was more pronounced in the middle
aged. It remains speculative whether chemoimmunothera-
py is responsible for this improvement, even though more
intensive treatment usually leads to higher toxicity and
mortality in this age group [12]. Maybe the introduction
of the relatively low toxicity antibody monotherapy in this
age group, either as a replacement of chemotherapy in re-
lapsed or unfit patients or as an additional line of treat-
ment after chemotherapy, had a significant impact on sur-
vival. To our knowledge, comparison of overall survival
in elderly CLL patients treated with monoclonal antibody
monotherapy versus chemotherapy has not been investi-
gated in prospective comparative trials. Furthermore, im-
provements in supportive care or more thorough risk strat-
ification for treatment might have been beneficial for
survival. Newer drugs, such as B-cell receptor kinase in-
hibitors and BCL-2 inhibitors, that demonstrated a survival
advantage compared to chemoimmunotherapy in prospec-
tive randomised trials [15, 40] did not add to the observed
survival improvement between the first and the second
time periods, since they were introduced later.
In the other two age groups, the largest gain in relative sur-
vival for 5-year survival, even if not significant, was also
between the two first time periods. For 10-year survival,
those aged <65 years at diagnosis demonstrated the high-
est increase between 2002–2006 and 2007–2011, whereas
those aged 75 years or older again had most improved sur-
vival from 1997–2001 to 2002–2006. The relative survival
in the later time periods might be underestimated owing
to selective reporting of more severe cases. One possibil-
ity for such a bias is the aforementioned change in diag-
nostic criteria for CLL, which might have affected the last
two time periods. Furthermore, selective reporting delay
for asymptomatic or low-risk cases might particularly af-
fect the latest time period.
Females demonstrated better relative survival than males
in all time periods. Relative survival seems to diverge
between sexes with increasing survival time (data not
shown). In contrast, no clear tendency by calendar time is
visible, suggesting that advances in disease management
had no impact on differences in survival by sex. We as-
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sume that reasons for better relative survival in females are
biological differences mentioned in the former section.
Implications for health care
Given the relatively long survival and the putative ongoing
need for treatment, patients require lifelong follow-up with
or without treatment. Presumably the intensity and cost of
care heavily depends on the morbidity and treatment ap-
plied. Unfortunately, such data are not available from the
registry. Population-based treatment-free intervals or time
to next treatment combined with information about disabil-
ity might provide better estimates of healthcare costs than
incidence, mortality and survival rates alone.
Strength and limitations
This is the first population-based report on trends in in-
cidence, mortality and survival for CLL/SLL patients in
Switzerland.
Population coverage was not stable over time but increased
over time, reaching a coverage over 70% percent in the last
time period.
The incidence rates presented here likely underestimate
true incidences in recent years because of reporting delay
and underreporting. Currently, NICER provides no model
to estimate incidence rates adjusted for reporting delay.
The registry data do not include information about treat-
ment. Therefore, we cannot directly infer how much the
development of treatment practice has contributed to im-
provement in survival. Furthermore, the registry does not
include any information about disease stage or biomarkers,
such as IGHV mutational status or TP53 aberrations.
Our selection of five-year time intervals for calendar time
periods and the grouping into three age groups for age-spe-
cific analysis may blur more detailed trends and age differ-
ences. Unfortunately, statistical inference from a finer res-
olution is limited due to case numbers.
Conclusion
There was no evidence of change in age-adjusted incidence
rates during the observed time period. The estimated age-
adjusted incidence rates are within the range of incidence
rates reported from other European countries. Mortality
significantly improved. Overall, age-adjusted survival im-
proved with the greatest improvement for those aged
65–74 years at diagnosis. CLL/SLL has striking sex dif-
ferences, with higher incidence rates, higher mortality and
shorter survival for males. We assume that the survival im-
provement is due to advances in treatment, even though
the data presented are not linked to individual treatment
information. Biases from reporting delay, underreporting
and changes in diagnostic criteria are major limitations and
hamper more accurate interpretation of the registry data.
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Appendix
Supplementary data
Figure S1: Age-standardised relative survival curves of chronic
lymphocytic leukaemia / small lymphocytic lymphoma patients by
time period.

























Managed by one cancer registry (CR): * CR Basel-City and Basel-Country; † CR Glarus-Graubünden; ‡ CR Neuchâtel and Jura; § CR Central Switzerland; ¶ CR East Switzerland;
‖ CR Zurich and Zug
Table S2: Type of verification of the diagnosis by time period and diagnosis code.
Time period CLL (ICD-O-code 9823/3), n (%) SLL (ICD-O-code 9670/3), n (%)
Morphologically verified Other Morphologically verified Other
Cytological Histological Cytological Histological
1997–2001 317 (32.4) 596 (60.9) 66 (6.7) 8 (3.6) 213 (96.0) 1 (0.5)
2002–2006 466 (37.3) 689 (55.1) 96 (7.7) 21 (9.5) 200 (90.1) 1 (0.5)
2007–2011 591 (45.1) 641 (48.9) 80 (6.1) 15 (6.0) 235 (94.0) 0 (0.0)
2012–2016 979 (56.4) 685 (39.5) 71 (4.1) 16 (4.9) 312 (94.6) 2 (0.6)
CLL = chronic lymphatic leukaemia; SLL = small lymphocytic lymphoma
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Table S3: Age-adjusted incidence of chronic lymphocytic leukaemia / small lymphocytic lymphoma in Switzerland, 1997–2016.
Standard 1997–2001 2002–2006 2007–2011 2012–2016
Rate* (95% CI) Rate* (95% CI) Rate* (95% CI) Rate* (95% CI)
Males
Euro 2013 9.6 (8.8–10.3) 10.8 (10.0–11.5) 9.4 (8.8–10.1) 8.9 (8.4–9.4)
Euro 1976 6.0 (5.5–6.4) 6.8 (6.3–7.3) 5.8 (5.4–6.2) 5.6 (5.3–5.9)
WHO World 4.5 (4.2–4.9) 5.2 (4.8–5.5) 4.4 (4.1–4.7) 4.3 (4.0–4.5)
Segi’s World 3.9 (3.6–4.3) 4.5 (4.2–4.8) 3.8 (3.6–4.1) 3.7 (3.5–3.9)
Females
Euro 2013 5.3 (4.9–5.8) 5.7 (5.2–6.1) 5.2 (4.8–5.6) 4.4 (4.1–4.7)
Euro 1976 3.3 (3.0–3.7) 3.6 (3.3–3.9) 3.2 (3.0–3.5) 2.8 (2.6–3.0)
WHO World 2.6 (2.3–2.8) 2.7 (2.5–2.9) 2.5 (2.3–2.7) 2.1 (2.0–2.3)
Segi’s World 2.2 (2.0–2.5) 2.3 (2.1–2.6) 2.1 (2.0–2.3) 1.9 (1.7–2.0)
Both sexes
Euro 2013 7.0 (6.6–7.4) 7.8 (7.4–8.2) 7.0 (6.6–7.4) 6.4 (6.1–6.7)
Euro 1976 4.4 (4.2–4.7) 5.0 (4.7–5.3) 4.4 (4.1–4.6) 4.1 (3.9–4.3)
WHO World 3.4 (3.2–3.6) 3.8 (3.6–4.0) 3.3 (3.1–3.5) 3.1 (3.0–3.3)
Segi’s World 3.0 (2.8–3.2) 3.3 (3.1–3.5) 2.9 (2.8–3.1) 2.7 (2.6–2.9)
CI = confidence interval * per 100,000 person-years
Table S4: Age-adjusted mortality of chronic lymphocytic leukaemia / small lymphocytic lymphoma in Switzerland, 1997–2016.
Standard 1997–2001 2002–2006 2007–2011 2012–2016
Rate* (95% CI) Rate* (95% CI) Rate* (95% CI) Rate* (95% CI)
Males
Euro 2013 3.6 (3.2–4.0) 3.7 (3.3–4.0) 3.3 (3.0–3.6) 3.0 (2.7–3.3)
Euro 1976 1.8 (1.6–2.0) 1.8 (1.7–2.0) 1.6 (1.5–1.8) 1.4 (1.3–1.6)
WHO World 1.3 (1.2–1.5) 1.4 (1.2–1.5) 1.2 (1.1–1.3) 1.1 (1.0–1.2)
Segi’s World 1.1 (1.0–1.2) 1.1 (1.0–1.2) 1.0 (0.9–1.1) 0.8 (0.7–0.9)
Females
Euro 2013 1.7 (1.5–1.9) 1.7 (1.5–1.9) 1.7 (1.5–1.8) 1.4 (1.2–1.6)
Euro 1976 0.9 (0.8–1.0) 0.8 (0.8–1.0) 0.8 (0.7–0.9) 0.7 (0.6–0.8)
WHO World 0.7 (0.6–0.7) 0.6 (0.6–0.7) 0.6 (0.5–0.7) 0.5 (0.4–0.5)
Segi’s World 0.5 (0.4–0.6) 0.5 (0.4–0.6) 0.5 (0.4–0.5) 0.4 (0.3–0.4)
Both sexes
Euro 2013 2.4 (2.2–2.6) 2.4 (2.3–2.6) 2.3 (2.2–2.5) 2.0 (1.9–2.2)
Euro 1976 1.2 (1.1–1.3) 1.2 (1.2–1.3) 1.2 (1.1–1.2) 1.0 (0.9–1.1)
WHO World 0.9 (0.9–1.0) 0.9 (0.9–1.0) 0.9 (0.8–0.9) 3.1 (1,4–5.3)
Segi’s World 0.7 (0.7–0.8) 0.7 (0.7–0.8) 0.7 (0.6–0.7) 0.7 (0.7–0.8)
CI = confidence interval * per 100,000 person-years
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Table S5: Observed and relative survival of chronic lymphocytic leukaemia / small lymphocytic lymphoma patients by age-group and period.
1-year survival 3-year survival 5-year survival 10-year survival
OS RS* (95% CI) OS RS* (95% CI) OS RS* (95% CI) OS RS* (95% CI)
<65 years
1997–2001 97.5 98.1 (95.6–99.4) 92.7 94.7 (91.2–97.2) 85.3 88.8 (84.0–92.5) 64.0 71.0 (63.9–77.3)
2002–2006 98.5 99.1 (97.3–99.9) 94.2 96.1 (93.0–98.1) 89.5 92.7 (88.8–95.6) 66.6 72.9 (66.6–78.4)
2007–2011 99.2 99.7 (98.1–100.3) 96.1 97.7 (95.3–99.3) 91.8 94.7 (91.4–97.1) 75.3 81.5 (76.1–86.2)
2012–2016 98.3 98.7 (97.1–99.5) 93.6 94.9 (92.2–96.9) 90.4 92.9 (89.5–95.5) 73.0 78.4 (73.1–83.0)
65–74 years
1997–2001 91.3 93.2 (89.5–95.8) 80.2 85.8 (80.6–90.0) 69.5 78.7 (72.5–84.2) 37.2 51.2 (43.1–59.3)
2002–2006 95.4 97.1 (94.4–98.8) 84.6 89.7 (85.1–93.3) 76.9 85.6 (80.1–90.3) 52.3 69.9 (61.9–77.5)
2007–2011 95.3 96.7 (94.2–98.4) 87.5 92.2 (88.5–95.1) 79.9 87.8 (83.2–91.6) 51.0 65.7 (58.7–72.4)
2012–2016 96.5 97.8 (95.8–99.1) 90.3 94.4 (91.2–96.8) 80.3 87.3 (82.8–91.0) 53.9 67.5 (60.8–73.8)
75+ years
1997–2001 75.6 81.5 (76.3–86.0) 54.9 69.7 (62.9–76.2) 39.9 61.6 (53.4–69.6) 12.0 35.1 (24.7–47.4}
2002–2006 81.9 87.9 (83.9–91.4) 61.8 77.1 (71.3–82.5) 46.9 69.1 (61.9–76.1) 17.8 46.6 (35.9–58.4)
2007–2011 86.4 92.1 (88.6–95.0) 65.2 80.3 (74.8–85.4) 49.1 71.1 (64.3–77.6) 17.9 43.9 (34.8–53.9)
2012–2016 84.5 90.1 (86.7–92.9) 64.4 78.8 (73.7–83.4) 45.9 65.2 (59.0–71.2) 15.8 36.9 (29.2–45.5)
All ages†
1997–2001 89.4 91.9 (89.9–93.5) 78.1 84.8 (81.8–87.3) 67.7 77.9 (74.2–81.2) 42.3 55.6 (50.5–60.3)
2002–2006 92.9 95.3 (93.8–96.5) 82.0 88.5 (86.0–90.6) 73.4 83.5 (80.3–86.3) 49.2 64.9 (60.0–69.3)
2007–2011 94.4 96.6 (95.2–97.6) 84.6 91.0 (88.7–92.8) 76.0 85.7 (82.9–88.1) 52.7 66.7 (62.6–70.5)
2012–2016 93.8 96.0 (94.7–96.9) 84.4 90.2 (88.2–91.9) 75.1 83.6 (81.0–85.8) 52.1 64.2 (60.4–67.6)
CI = confidence interval; OS = observed survival; RS = relative survival * presented in percentages † age-standardised observed and relative survival
Table S6: Patient characteristics of chronic lymphocytic leukaemia / small lymphocytic lymphoma cases reported to Swiss cancer registries, 1997–2016 (sensitivity analyses).
n % Median age at diagnosis (interquartile range)
Overall 5446 100.0% 72 (63–80)
Sex
Males 3169 58.2% 71 (62–78)
Females 2277 41.8% 74 (65–81)
Age
<65 years 1524 28.0% –
65–74 years 1696 31.1% –
75–84 years 2226 40.9% –
Time period –
1997–2001 1201 22.1% 72 (63–79)
2002–2006 1452 26.7% 71.5 (62–79)
2007–2011 1428 26.2% 72 (64–80)
2012–2016 1365 25.1% 72 (63–80)
Population covered by cancer registration: 57.8% in 1997–2001, 57.9% in 2002–2006, 58.2% in 2007–2011, and 56.1% in 2012–2016
Table S7: Incidence of chronic lymphocytic leukaemia / small lymphocytic lymphoma in Switzerland, 1997–2016 (sensitivity analyses).














Crude Adjusted‡ Crude Adjusted‡ Crude Adjusted‡ Crude Adjusted‡
Incidence
Overall 409 5.8 7.0 496 6.8 7.8 490 6.3 7.1 491 5.9 6.4
Sex
Males 231 6.7 9.6 291 8.1 10.8 283 7.4 9.5 302 7.4 8.8
Females 178 5.0 5.3 205 5.5 5.7 207 5.3 5.4 189 4.6 4.5
Age
<65 years 117 2.0 2.3 146 2.4 2.6 129 2.0 2.1 140 2.0 2.1
65-74 years 130 22.3 22.3 145 23.9 24.0 157 23.3 23.6 154 19.9 20.0
75+ years 162 31.8 31.7 205 36.4 36.4 204 32.9 32.6 197 29.2 29.0
* Incidence: mean annual case frequency extrapolated to the whole Swiss population from cases observed in the cancer registries. † per 100,000 person-years. ‡ European
Standard 2013.
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